Home › Research › Tau biomarkers
African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants
Schindler SE, Cruchaga C, Joseph A, McCue L, Farias FHG, Wilkins CH, Deming Y, Henson RL et al.. Neurology. Genetics, 2021-03-04
Topic: Brain proteins, microglia and lab models
Objective To evaluate for racial differences in triggering receptor expressed on myeloid cells 2 (TREM2), a key immune mediator in Alzheimer disease, the levels of CSF soluble TREM2 (sTREM2), and the frequency of associated genetic variants were compared in groups of individuals who self-reported their race as African American (AA) or non-Hispanic White (NHW). Methods Community-dwelling older research participants underwent measurement of CSF sTREM2 concentrations and genetic analyses. Results The primary cohort included 91 AAs and 868 NHWs.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Schindler, S. E., Cruchaga, C., Joseph, A., McCue, L., Farias, F. H. G., Wilkins, C. H., et al. (2021). African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. Neurology. Genetics. https://doi.org/10.1212/nxg.0000000000000571
Vancouver
Schindler SE, Cruchaga C, Joseph A, McCue L, Farias FHG, Wilkins CH, et al. African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. Neurology. Genetics. 2021. doi:10.1212/nxg.0000000000000571. PMID: 33884297.
BibTeX
@article{schindler2021-33884297,
author = {Schindler, S. E. and Cruchaga, C. and Joseph, A. and McCue, L. and Farias, F. H. G. and Wilkins, C. H. and Deming, Y. and Henson, R. L. and others},
title = {{African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants}},
journal = {Neurology. Genetics},
year = {2021},
doi = {10.1212/nxg.0000000000000571},
pmid = {33884297},
url = {https://doi.org/10.1212/nxg.0000000000000571}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Methods Community-dwelling older research participants underwent measurement of CSF sTREM2 concentrations and genetic analyses.
- Results The primary cohort included 91 AAs and 868 NHWs.
- CSF sTREM2 levels were lower in the AA compared with the NHW group (1,336 ± 470 vs 1,856 ± 624 pg/mL, p TREM2 coding variants (15% vs 3%, p p MS4A4A , which was associated with higher CSF sTREM2.
- These findings were replicated in an independent cohort of 23 AAs and 917 NHWs: CSF sTREM2 levels were lower in the AA group ( p = 0.03), AAs were more likely to carry coding TREM2 variants (22% vs 4%, p = 0.002), and AAs were less likely to carry the rs1582763 minor allele (16% vs 37%, p = 0.003).
Why it matters
This study compared cerebrospinal fluid soluble TREM2 levels and associated genetic variants between African American and non-Hispanic White participants. It describes racial differences in an immune-related marker, not a treatment, cure, or prevention for Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants91
- Evidence strengthModerate
How this study scored 52/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurology. Genetics) |
| Journal's citation record | 0 / 4 | Neurology Genetics: journal h-index 53 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 91 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 49 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.0 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 3 / 6 | Cited 3.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 2 / 4 | Cited 22 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author John C. Morris: h-index 209 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33884297) |
| Free to read | 2 / 2 | Free to read |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/nxg.0000000000000571
- PubMed: 33884297
- Original source →
- Free full text: Neurology Genetics →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 34.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Tau biomarkers
Also tagged “macrophages”
363 studies in the library carry the topic tag “macrophages”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.